The Rising Challenge of Multidrug-Resistant Gram-Negative Infections in the Outcome of Hematological Oncology: A Review

Justy Babu *

Department of Microbiology, MAHER, Chennai, India.

S. Sivamalar

Department of Microbiology, MAHER, Chennai, India.

*Author to whom correspondence should be addressed.


Bloodstream infections (BSIs) caused by Gram-negative bacteria (GNB) are a significant concern in patients with hematological malignancies (HM), particularly when multidrug-resistant (MDR) strains are involved. This review synthesizes key findings from studies investigating the epidemiology, clinical implications, and management strategies for GNB BSIs in HM patients. The reviewed studies shows the heightened mortality risk associated with GNB BSIs, especially in the context of immunocompromised HM patients. Studies highlight the prevalence of MDR GNB, including ESBL, AmpC β-lactamase, and carbapenemase-producing strains, which pose challenges to standard antibacterial therapies. Importantly, the review identifies the need for routine blood culture monitoring, personalized risk assessment, and tailored antimicrobial policies to optimize patient outcomes. Most important MDR groups identified were Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, Stenotrophomonas maltophilia, Proteus species. Future research directions include enhancing surveillance systems, developing innovative therapeutic approaches, personalized medicine strategies, strengthening infection control measures, optimizing antimicrobial prophylaxis, and investigating antibiotic-resistant strains and gene identification.

Keywords: Gram-negative bacteria, hematological malignancies, multidrug resistance, mortality risk, antimicrobial therapy, infection control, treatment strategy

How to Cite

Babu, Justy, and S. Sivamalar. 2024. “The Rising Challenge of Multidrug-Resistant Gram-Negative Infections in the Outcome of Hematological Oncology: A Review”. International Research Journal of Oncology 7 (2):178-85.


Download data is not yet available.


Chumbita M, Puerta-Alcalde P, Yáñez L, Angeles Cuesta M, Chinea A, Español-Morales I, Garcia-Vidal C. High rate of inappropriate antibiotics in patients with hematologic malignancies and Pseudomonas aeruginosa bacteremia following international guideline recommendations. Microbiology Spectrum, 2023;11(4):e00674-23. Available:

Trecarichi EM, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, Marchesi F, Laurino M, Dargenio M, Fanci R, Cefalo M, Delia M, Spolzino A, Maracci L, Bonuomo V, Busca A, Principe MID, Daffini R, Simonetti E, Dragonetti G. Hematologic Malignancies Associated Bloodstream Infections Surveillance (HEMABIS) registry – Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne (SEIFEM) group, Italy Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey. International Journal of Antimicrobial Agents. 2023;61(6): 106806. Available:

Baker TM, Satlin MJ. The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. Leukemia & Lymphoma. 2016;57(10):2245–2258. Available:

Fritsche G. Clinically relevant infections in hematology and oncology: bacterial infections and the role of novel antibiotics in times of multidrug resistance. memo-Magazine of European Medical Oncology. 2021;14(3):292-7.

Baker TM, Satlin MJ. The growing threat of multidrug-resistant gram-negative infections in patients with hematologic malignancies. Leukemia & lymphoma. 2016;57(10):2245-58.

Secreto C, Busca A, Lupia T, Corcione S, De Rosa FG. The management of hematologic patients with bloodstream infections due to multi-drug resistant bacteria: Where do we stand? From antibacterial prophylaxis to the treatment of septic shock. Hemato. 2020;1(2):60- 76. Available:

Dhanaraj N, Foppiano Palacios C. The role of repeated blood cultures in hematologic malignancy patients with neutropenic fever due to gram-negative bacterial bloodstream infections. Open Forum Infectious Diseases. 2023; 10(Supplement_2):ofad500.259.


Al-Otaibi FE, Bukhari EE, Badr M, Alrabiaa AA. Prevalence and risk factors of Gram-negative bacilli causing blood stream infection in patients with malignancy. Saudi Medical Journal. 2016; 37(9):979–984. Available:

Rajeswari B, Nair RKS, Guruprasad CS, Nair M, Thankamony P, Parukutty K. Infections during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia – Profile and Outcomes: Experience from a Cancer Center in South India. Indian Journal of Medical and Paediatric Oncology. 2018;39(2):188-192.DOI: 10.4103/ijmpo.ijmpo_95_17.

Batra U, Goyal P, Jain P, Upadhyay A, Sachdeva N, Agarwal M, Bhurani D, Talwar V, Gupta SK, Doval DC. Epidemiology and resistance pattern of bacterial isolates among cancer patients in a Tertiary Care Oncology Centre in North India. Indian Journal of Cancer. 2016;53(3):448–451. Available:

Radhakrishnan V, Vijaykumar V, Ganesan P, Rajendranath R, Trivadi G, Tenali S. Bloodstream infections in pediatric patients at Cancer Institute, Chennai. Indian journal of Cancer. 2014;51(4):418–419. Available:

Tohamy ST, Aboshanab KM, El-Mahallawy HA, El-Ansary MR, Afifi SS. Prevalence of multidrug-resistant Gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations. Infection and Drug Resistance. 2018; 11:791–803.Available:

Mukherjee S, De MS, Goel G, Bhattacharyya A, Mallick I, Dabkara D, Bhaumik J, Roy MK, Majumdar PB, Chatterji S, Mukherjee S, Bhattacharya S, Chandy M. Multi-drug resistant (MDR) and extensively drug-resistant (XDR) bacteraemia rates among cancer patients in an oncology hospital in eastern India: An 11-year retrospective observational study. Infection Prevention in Practice. 2023;5(2): 100275. Available:

Talukdar A, Barman R, Hazarika M, Das G. Bloodstream infections in paediatric cancer patients with febrile neutropenia in a tertiary cancer centre in North-East India. Asian Pacific Journal of Cancer Care. 2023;8(4):691-695. Available:

Lubwama M, Bwanga F, Kateete D, Adams S, Namubiru B, Nabiryo B, Orem J, Phipps W. Multidrug resistant polymicrobial Gram-negative bacteremia in hematologic cancer patients with febrile neutropenia at the Uganda Cancer Institute. Open Forum Infectious Diseases. 2021;8 (Supplement_1):S220–S221. Available:

Nucci M, Anaissie EJ. Prevention of Infections in patients with hematological malignancies. Neoplastic Diseases of the Blood. 2017;1047–1062. Available:

Wilson BJ. Prevention of infection: A systematic review of evidence-based practice interventions for management in patients with cancer. Number 2/April 2018; 22(2):157-168. DOI: 10.1188/18.CJON.157-168

Mattei D, Baretta V, Mazzariol A, Maccacaro L, Balter R, Zaccaron A, Cesaro S. Characteristics and outcomes of Bloodstream Infections in a Tertiary-Care Pediatric hematology–oncology unit: A 10-Year study. Journal of Clinical Medicine. 2022;11(3):880.

Alexander S, Nieder M, Zerr DM, Fisher BT, Dvorak CC, Sung L. Prevention of bacterial infection in pediatric oncology: What do we know, what can we learn?. Pediatric Blood & Cancer. 2012; 59(1):16-20. Available:

Chen S, Lin K, Li Q, Luo X, Xiao M, Chen M, Yang T. A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy. Journal of Cancer. 2021;12(18):5494.

Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. Virulence. 2016;7(3):280-297. Available:

Ali Y, Inusa I, Sanghvi G, Mandaliya VB, Bishoyi AK. The current status of phage therapy and its advancement towards establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. Microbial Pathogenesis. 2023; 181:106199.

Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MFR, Hassan MM. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Frontiers in Oncology. 2022;12:891652.